Clinical Core

核心B：临床项目总结 核心B：临床招募、评估和随访Knight ADRC队列的所有参与者。它使用得很好- 建立基于信息的临床和心理测量工具（包括统一数据集） 此后每年收集临床、认知、行为和神经学数据， 每个参与者是否存在痴呆症，如果存在，其严重程度和病因。的 核心已成功地发挥作用，以满足骑士ADRC尖端研究项目的需求， 自1985年成立以来，其附属赠款一直在增加，并将在下一个五年供资期内继续这样做。的 核心小组在拟议供资期间的具体目标是： 1.维持当前活跃的受试者队列（当前N=272），仔细描述是否存在 或没有症状性AD，以支持临床、认知和生物医学的纵向研究。 与认知正常老化相比，症状性AD的相关性，并标志着 从临床前AD患者到认知障碍。 2.每年入组并评估40名年龄≥ 65岁的新受试者（症状性个体为50岁或以上）， 以补充损耗，并将现役部队扩大到约350人。 3.收集数据、图像和生物标本（DNA、CSF、血浆、真皮成纤维细胞和iPSC）， 与会者酌情。 4.对所有参与者进行脑部解剖。 5.继续让圣路易斯非裔美国人社区的个人参与， 非裔美国人在研究。 6.结合研究教育部分，使用核心资源进行早期培训 研究人员在痴呆评估，ADRD的异质性，和临床病理学的相关性， 探索AD的多因素性质。 7.继续确保广泛共享Knight ADRC工具、数据和生物标本，并继续 对多中心ADRD项目的贡献。 8.处理与认知数据、纵向分子表型分析、性别 以及种族差异、睡眠和血管对痴呆的影响。

Core B: Clinical Project Summary Core B: Clinical recruits, assesses, and follows all participants in the Knight ADRC Cohort. It uses well- established informant-based clinical and psychometric instruments (including the Uniform Data Set) at entry and annually thereafter to obtain clinical, cognitive, behavioral, and neurological data to carefully characterize each participant as to the presence or absence of dementia and, when present, its severity and etiology. The Core has successfully functioned to serve the needs of cutting-edge research projects of the Knight ADRC and its affiliated grants since its inception in 1985 and will continue to do so in the next 5-year funding period. The Core's Specific Aims in the proposed funding period are: 1. Maintain an current active cohort of participants (current N=272), carefully characterized as to the presence or absence of symptomatic AD, to support longitudinal studies of the clinical, cognitive, and biomedical correlates of symptomatic AD in comparison with cognitively normal aging and to mark the transition of participants with preclinical AD to cognitive impairment. 2. Annually enroll and assess 40 new participants age 65y or older (50y or older for symptomatic individuals), to replenish attritional losses and expand the active cohort to ~350. 3. Collect data, images, and biospecimens (DNA, CSF, plasma, dermal fibroblasts, and iPSCs) from participants as appropriate. 4. Solicit brain autopsy from all participants. 5. Continue to engage individuals in the African American community in St. Louis to promote the inclusion of African Americans in research. 6. In conjunction with the Research Education Component, use Core resources to train early stage investigators in dementia assessment, the heterogeneity of ADRD, and clinicopathological correlations that explore the multifactorial nature of AD. 7. Continue to ensure the broad sharing of Knight ADRC tools, data, and biospecimens and continue contributions to multicenter ADRD programs. 8. Address appropriate NAPA milestones related to cognitive data, longitudinal molecular phenotyping, sex and racial differences, sleep, and vascular contributions to dementia.